Based on the results, we highlighted PI3K and mTOR as good candidates and PI3K signaling pathway inhibitors as potential treatment options that are interesting enough to be further explored, although we described other targets that could also be further evaluated to test their effect in improving the phenotype of SLE, such as PKC, MAPK, or other specific kinases. Here, PRRT2 is linked to systemic lupus erythematosus.